Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease of serum buffering capacity associated with malignant neoplasms.

K Nakamura1, Y Nakajima, Y Nakamura

  • 1Department of Biochemistry, Molecular Biology Laboratory, University School of Medicine, Kanagawa, Japan.

Cancer Detection and Prevention
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monobody adapter for functional antibody display on nanoparticles for adaptable targeted delivery applications.

Nature communications·2022
Same author

The Production of Flocculating Substance(s) by Streptomyces griseus.

Bioscience, biotechnology, and biochemistry·2016
Same author

Possible involvement of LKB1-AMPK signaling in non-homologous end joining.

Oncogene·2013
Same author

Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors.

Oncogene·2011
Same author

Laser Doppler velocimeter with a differential photodiode array.

Applied optics·2010
Same author

Optical waveguide 3x3 switch: theory of tuning and control.

Applied optics·2010
Same journal

Melanoma metastasis to the breast: a diagnostic pitfall.

Cancer detection and prevention·2009
Same journal

Development of a rat model by 3,4-benzopyrene intra-pulmonary injection and evaluation of the effect of green tea drinking on p53 and bcl-2 expression in lung carcinoma.

Cancer detection and prevention·2009
Same journal

Combined effect of NAT2, MTR and MTHFR genotypes and tobacco on bladder cancer susceptibility in Tunisian population.

Cancer detection and prevention·2009
Same journal

Vitamin D receptor gene polymorphism(s) and breast cancer risk in north Indians.

Cancer detection and prevention·2009
Same journal

Epidemiology of primary brain tumors in the Middle Eastern population in California, USA 2001-2005.

Cancer detection and prevention·2009
Same journal

Lifetime consumption of alcoholic beverages and risk of 13 types of cancer in men: results from a case-control study in Montreal.

Cancer detection and prevention·2009
See all related articles

Cancerous sera inhibit macrophage glucose utilization via phosphofructokinase (PFK) suppression. This PFK inhibition test offers a novel tumor marker, correlating with serum buffering capacity and lactate levels.

Area of Science:

  • Biochemistry
  • Oncology
  • Immunology

Background:

  • Cancerous sera exhibit altered metabolic effects on immune cells.
  • Phosphofructokinase (PFK) is a key regulatory enzyme in glycolysis.
  • Macrophage glucose utilization is sensitive to serum factors.

Purpose of the Study:

  • To identify a novel tumor marker based on serum-mediated suppression of macrophage glucose utilization.
  • To investigate the role of phosphofructokinase (PFK) in this suppressive effect.
  • To correlate PFK inhibition with serum buffering capacity and lactate levels in cancer patients.

Main Methods:

  • Cultured macrophages were exposed to sera from cancerous and healthy donors.
  • Glucose utilization by macrophages was measured.

Related Experiment Videos

  • Phosphofructokinase (PFK) activity was assessed.
  • Serum buffering capacity against ATP and acidic solutions was determined.
  • Lactate levels in sera were quantified.

    • Main Results:

    • Cancerous sera significantly suppressed glucose utilization by macrophages.
    • Phosphofructokinase (PFK) was identified as the enzyme targeted by cancerous sera.
    • A high correlation was observed between PFK inhibition and reduced serum buffering capacity.
    • Cancerous sera contained 1.6 times more lactate than normal sera.
    • Sera from patients with acidosis (diabetes, renal failure, pregnancy) also showed PFK inhibition and lower buffering capacity.

    Conclusions:

    • PFK inhibition serves as a potential tumor marker.
    • The PFK inhibition test reflects both reduced serum buffering capacity and enzyme inactivation via oxidation.
    • This assay may provide a more comprehensive assessment than simple pH measurements.